Search Result

Results for "

Ceramides

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (4) Apoptosis (23) Autophagy (4) Bacterial (2) Bcl-2 Family (1) Biochemical Assay Reagents (37) Cannabinoid Receptor (1) Caspase (1) Ceramidase (5) COX (1) CXCR (2) Dihydroceramide Desaturase 1 (DES1) (1) DNA/RNA Synthesis (1) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (4) Endogenous Metabolite (30) Estrogen Receptor/ERR (3) Filovirus (1) Fluorescent Dye (16) Fungal (1) GCGR (2) Glucosylceramide Synthase (GCS) (8) Glycosidase (1) GSK-3 (1) iGluR (1) Interleukin Related (2) Isotope-Labeled Compounds (35) Liposome (11) LPL Receptor (2) MDM-2/p53 (2) Mitochondrial Metabolism (2) Neuropeptide Y Receptor (3) Parasite (2) PARP (1) Phosphatase (1) Phospholipase (5) PI3K (1) PKC (7) Reference Standards (2) SphK (1) Telomerase (1) UGT (1) β-catenin (1)
By Research Areas:	Cancer (37) Cardiovascular Disease (3) Endocrinology (3) Infection (8) Inflammation/Immunology (13) Metabolic Disease (47) Neurological Disease (30)
Oligonucleotides:	Pegylated Lipids (3) Phospholipids (2)

191

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113679

Ceramides Mixture 1 Publications Verification	Telomerase	Metabolic Disease Endocrinology
Ceramides Mixture is an endogenous ceramide and consists of hydroxy and non-hydroxy fatty acid-containing ceramides. Ceramides Mixture is a main lipid component of the permeability barrier in epidermis. Ceramides Mixture is involved in the regulation of growth inhibition, cell cycle arrest, and modulation of telomerase activity .

HY-124177A

*C14 Ceramide* (d18:1/14:0)**	Endogenous Metabolite	Neurological Disease Metabolic Disease
C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research .

HY-141578

C18:1-Ceramide	Endogenous Metabolite	Metabolic Disease
C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes

HY-144005

C16 PEG2000 Ceramide C16 PEG Ceramide (MW 2000)	Liposome Autophagy	Cancer
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .

HY-134575

C24:1-Ceramide	Apoptosis GSK-3	Others
C24:1-Ceramide is one of the most abundant naturally occurring ceramide. Ceramides regulates many diverse biological activities, such as cell apoptosis, cell differentiation, proliferation of smooth muscle cells, and inhibition of the mitochondrial respiratory chain .

HY-19542S1

*C6 Ceramide-d11* C6-Cer-d₁₁; N-Hexanoylsphingosine-d₁₁	Apoptosis Isotope-Labeled Compounds	Cancer
C6 Ceramide-d₁₁ is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-D1582

C12 NBD Phytoceramide	Fluorescent Dye	Others
C12 NBD Phytoceramide, a ceramide analogue, is a fluorescent substrate, can be used to detect ceramidase activity .

HY-165099

*C-8 Ceramide-1-phosphate*	Apoptosis PI3K DNA/RNA Synthesis	Metabolic Disease
C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .

HY-D1576

C6 NBD L-threo-dihydroceramide	Fluorescent Dye	Others
C6 NBD L-threo-dihydroceramide is a dihydro-ceramide isomer labeled with a fluorescent group C6 nitrobenzoxadiazole (C6 NBD), can be used to detect ceramide.

HY-E70281

Recombinant endoglycoceramidase II rEGCase II	Biochemical Assay Reagents	Metabolic Disease
Recombinant endoglycoceramidase II (rEGCase II) is an endo-β-glucosidase releasing the complete glycan from ceramide in glycosphingolipids. Recombinant endoglycoceramidase II catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides in various glycosphingolipids .

HY-132182

HPA-12	Others	Cancer
HPA-12 is an intracellular ceramide transport protein inhibitor .

HY-141575

C12-NBD-ceramide	Fluorescent Dye	Others
C12-NBD-ceramide is a fluorescent analogue of ceramide, it can be used as a substrate in ceramidase assays .

HY-D2256

BDP TMR ceramide	Fluorescent Dye	Neurological Disease
BDP TMR ceramide is a BDP TMR (a water-soluble dye with a high affinity to lipid bilayers) labeled ceramide. Ex: 542 nm, Em: 572 nm .

HY-108391

C8-Ceramide N-Octanoyl-D-erythro-sphingosine	Apoptosis PKC Autophagy	Inflammation/Immunology Cancer
C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .

HY-157418

1-Deoxy-Cer	Others	Others
1-Deoxy-Cer is a Ceramide which is essential component of the skin permeability barrier.

HY-103359

Ceranib1	Ceramidase	Cancer
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells .

HY-P1975

Aureobasidin A 2 Publications Verification Basifungin	Fungal Parasite	Infection Inflammation/Immunology
Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .

HY-101180

C2 Ceramide 1 Publications Verification Ceramide 2	Phosphatase Mitochondrial Metabolism Apoptosis Autophagy	Metabolic Disease Endocrinology
C2 Ceramide (Ceramide 2) is the main lipid of the stratum corneum and a protein phosphatase 1 (PP1) activator. C2 Ceramide activates PP2A and ceramide-activated protein phosphatase (CAPP). C2 Ceramide induces cells differentiation, autophagy and apoptosis, inhibits mitochondrial respiratory chain complex III. C2 Ceramide is also a skin conditioning agent that protects the epidermal barrier from water loss .

HY-19542

C6 Ceramide 2 Publications Verification C6-Cer; N-Hexanoylsphingosine	Apoptosis	Cancer
C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-D1573

C6 NBD Phytoceramide	Fluorescent Dye	Others
C6 NBD Phytoceramide is a fluorescently labeled short-chain ceramide analog that can be recognized by mammalian GlcCer synthase (GCS) .

HY-13626

Spisulosine ES-285	PKC Apoptosis	Cancer
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .

HY-P2936

Sphingomyelin phosphodiesterase, Streptomyces sp.	Phospholipase	Metabolic Disease
Sphingomyelin phosphodiesterase, Streptomyces sp., a hydrolase, is involved in the sphingomyelin metabolism process. Sphingomyelin phosphodiesterase hydrolyzes the conversion of sphingomyelin to phosphocholine and ceramide. Sphingomyelin phosphodiesterase also plays an important role in cellular differentiation, various immune and inflammatory responses, and intracellular cholesterol trafficking and metabolism .

HY-131703

UGT8-IN-1	UGT	Metabolic Disease
UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders .

HY-17020

Miglustat 5 Publications Verification N-Butyldeoxynojirimycin; NB-DNJ; OGT 918	Glucosylceramide Synthase (GCS)	Neurological Disease Inflammation/Immunology
Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease .

HY-17020A

Miglustat hydrochloride 5 Publications Verification N-Butyldeoxynojirimycin hydrochloride; NB-DNJ hydrochloride; OGT 918 hydrochloride	Glucosylceramide Synthase (GCS)	Neurological Disease Inflammation/Immunology
Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease .

HY-129099

N-Desmethyltamoxifen	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite	Cancer
N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-129099A

N-Desmethyltamoxifen hydrochloride	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite	Cancer
N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-E70280

Recombinant endoglycoceramidase I rEGCase I	Biochemical Assay Reagents	Metabolic Disease
Recombinant endoglycoceramidase I (rEGCase I) is a glycosidase that catalyzes the hydrolysis of the β-glycosidic linkage between oligosaccharides and ceramides. Recombinant endoglycoceramidase I catalyzes a transglycosylation reaction, which transfers the sugar moiety of glycosphingolipids (GSLs) to the primary hydroxyl group of several 1-alkanols .

HY-129099AR

N-Desmethyltamoxifen hydrochloride (Standard)	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite	Cancer
N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].

HY-114615

AMP-Deoxynojirimycin AMP-DNM	Glycosidase Glucosylceramide Synthase (GCS)	Neurological Disease
AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor .

HY-126015

P053 1 Publications Verification	Acyltransferase	Metabolic Disease
P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC₅₀ of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator .

HY-166315S

*C15-Ceramide-d7*	Isotope-Labeled Compounds Others	Metabolic Disease
C15-Ceramide-d₇ is deuterium labeled C15-Ceramide. C15-Ceramide is an ester product .

HY-D1579

C12 NBD Globotriaosylceramide	Fluorescent Dye	Others
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside .

HY-100353R

*C12-Ceramide* (Standard)** N-Lauroyl-D-erythro-sphingosine (Standard); N-Laurylsphingosine (Standard)	Reference Standards Others	Metabolic Disease Cancer
C12-Ceramide (Standard) is the analytical standard of C12-Ceramide. This product is intended for research and analytical applications. C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .

HY-100354S3

*C16-Ceramide-d9*	Isotope-Labeled Compounds Endogenous Metabolite	Others
C16-Ceramide-d₉ is deuterium labeled C16-Ceramide.

HY-100354S4

*C16-Ceramide-d31*	Endogenous Metabolite	Others
C16-Ceramide-d₃₁ is deuterium labeled C16-Ceramide.

HY-100355S1

*C18-Ceramide-d7*	Isotope-Labeled Compounds Endogenous Metabolite	Others
C18-Ceramide-d₇ is deuterium labeled C18-Ceramide.

HY-116147

Ceranib-2	LPL Receptor Apoptosis	Cancer
Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC₅₀ of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity .

HY-100355R

*C18-Ceramide* (Standard)**	Endogenous Metabolite Reference Standards	Neurological Disease Cancer
C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .

HY-145467

*C16 Ceramide-1-phosphate (d18:1/16:0) ammonium* C16 Ceramide-1-phosphate ammonium; Ceramide-1-phosphate (d18:1/16:0) ammonium; CerP(d18:1/16:0) ammonium	Biochemical Assay Reagents	Metabolic Disease
C16 Ceramide-1-phosphate (d18:1/16:0) (ammonium) (C16 Ceramide-1-phosphate (ammonium); Ceramide-1-phosphate (d18:1/16:0) (ammonium)) is an ester product.

HY-134508

C24-Ceramide	Liposome	Others
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .

HY-100355S

*C18-Ceramide-d3*	Isotope-Labeled Compounds	Others
C18-Ceramide-d₃ is the deuterium labeled C18-Ceramide[1].

HY-134508S

*C24-Ceramide-d7*	Isotope-Labeled Compounds	Others
C24-Ceramide-d₇ is the deuterium labeled C24-Ceramide[1].

HY-146902S

*C15 Ceramide-1-phosphate-d7*	Isotope-Labeled Compounds	Others
C15 Ceramide-1-phosphate-d₇ is deuterium labeled C15 Ceramide-1-phosphate.

HY-154831

C22-Ceramide N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0	Liposome	Metabolic Disease
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .

HY-134575S

*C24:1-Ceramide-d7*	Isotope-Labeled Compounds	Others
C24:1-Ceramide-d₇ is the deuterium labeled C24:1-Ceramide[1].

HY-119312

C8 Dihydroceramide	PKC	Cancer
C8 Dihydroceramide is a negative control of C8 Ceramide. C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro .

HY-141578S

*C18:1-Ceramide-13C18*	Isotope-Labeled Compounds	Others
C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

HY-163472

PR280	Dihydroceramide Desaturase 1 (DES1)	Metabolic Disease Cancer
PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) (IC₅₀=700 nM). PR280 forms hydrogen bonds with the amino acid residues of Des1, and its cyclopropenone group may form a coordination with the iron center, thus stabilizing the binding to the active site of Des1 and inhibiting the sphingosine lipid synthesis pathway of dihydroceramide (dhCer) to form ceramide. PR280 can be used in the study of diseases related to sphingosine lipid metabolism, such as cancer and metabolic diseases .

HY-100353

C12-Ceramide N-Lauroyl-D-erythro-sphingosine; N-Laurylsphingosine	Endogenous Metabolite	Metabolic Disease Cancer
C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .

Cat. No.	Product Name	Type

HY-D1612

BODIPY FL C5-Ceramide

Fluorescent Dyes/Probes

The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye . BODIPY Fl C5-Ceramide is a Golgi-specific green fluorescent dye, which can visualise individual cells . Ex/Em= 505 nm/512 nm.

HY-W356116

C6 NBD Ceramide

Nbd-ceramide

Dyes

C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism .

HY-D1735

BODIPY TR Ceramide

Golgi-Red Tracke

Fluorescent Dyes/Probes

The Golgi apparatus is composed of flattened vesicles superimposed on each other by unit membranes. The flattened vesicles are round with expanded and perforated edges. The Golgi fluorescent probe is a BODIPY-labeled ceramide derivative, the synthesis of which occurs in the endoplasmic reticulum and can then be transported to the Golgi via ceramide transport protein (CERT) or vesicular translocation, allowing specific labeling of the dye. BODIPY TR Ceramide (Golgi-Red Tracke) is a Golgi-specific fluorescent dye, which can visualise individual cells . Ex/Em=589 nm/616 nm.

HY-D1582

C12 NBD Phytoceramide	Chromogenic Substrates
C12 NBD Phytoceramide, a ceramide analogue, is a fluorescent substrate, can be used to detect ceramidase activity .

HY-141575

C12-NBD-ceramide	Fluorescent Dyes/Probes
C12-NBD-ceramide is a fluorescent analogue of ceramide, it can be used as a substrate in ceramidase assays .

HY-D2256

BDP TMR ceramide	Fluorescent Dyes/Probes
BDP TMR ceramide is a BDP TMR (a water-soluble dye with a high affinity to lipid bilayers) labeled ceramide. Ex: 542 nm, Em: 572 nm .

HY-D1573

C6 NBD Phytoceramide	Fluorescent Dyes/Probes
C6 NBD Phytoceramide is a fluorescently labeled short-chain ceramide analog that can be recognized by mammalian GlcCer synthase (GCS) .

HY-D1579

C12 NBD Globotriaosylceramide	Fluorescent Dyes/Probes
C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside .

HY-D2255

BDP FL ceramide	Fluorescent Dyes/Probes
BDP FL ceramide, a highly fluorescent lipid, is a conjugate of green-emitting BDP FL fluorophore with sphingosine. BDP FL ceramide can be used for the visualization of the Golgi apparatus via fluorescence microscopy.The excitation wavelength is 503 nm and the emission wavelength is 509 nm .

HY-D1749

C6 NBD L-threo-ceramide	Fluorescent Dyes/Probes
C6 NBD L-threo-ceramide is a cell-permeable analog of ceramides that is tagged with a fluorescent group C6 nitrobenzoxadiazole (C6 NBD). It is rapidly transferred between liposomes, labels the Golgi apparatus, and is metabolized to C6 NBD sphingomyelin in BHK cells and V79 fibroblasts.

HY-W356117

C6 NBD Glucosylceramide	Fluorescent Dyes/Probes
C6 NBD Glucosylceramide is a glucosylceramide fluorescent derivative (Ex=466 nm, Em=535 nm). C6 NBD Glucosylceramide can be used to study the metabolism and internalization of glucosylceramide and also for the determination of glucosyl ceramide synthase activity .

HY-D1574

C6 NBD Sphingomyelin	Fluorescent Dyes/Probes
C6 NBD Sphingomyelin is a fluorescent short-chain analogue of Sphingomyelin (HY-113498). Chlamydia trachomatis acquires C6 NBD Sphingomyelin endogenously synthesizes from C6-NBD-ceramide and transportes to the chlamydial inclusion. C6 NBD Sphingomyelin can incorporate into the plasma membrane .

Cat. No.	Product Name	Type

HY-144005

C16 PEG2000 Ceramide C16 PEG Ceramide (MW 2000)	Drug Delivery
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .

HY-134508

C24-Ceramide	Drug Delivery
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .

HY-154831

C22-Ceramide N-Behenoyl-D-erythro-sphingosine; Cer d18:1/22:0	Drug Delivery
C22-Ceramide (Cer d18:1/22:0) is an endogenous bioactive sphingolipid. C22-Ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes .

HY-165099

C-8 Ceramide-1-phosphate

Drug Delivery

C-8 Ceramide-1-phosphate is a cell apoptosis inhibitor and a cell survival inducer that can stimulate DNA synthesis and cell division. C-8 Ceramide-1-phosphate can inhibit acidic sphingomyelinase (SMase) and stimulate PI3-K, which in turn produces PIP3; PIP3 can also inhibit acidic SMase. The C-8 Ceramide-1-phosphate and ceramide can be interconverted in cells through kinase and phosphatase activity, and maintaining the balance between the two is crucial for cellular and tissue homeostasis .

HY-W698686

β-Galactosyl-C18-ceramide

Cell Assay Reagents

β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

HY-W590667

*C2 Ceramide-1-phosphate*	Drug Delivery
C2 Ceramide-1-phosphate is a phospholipid. Phospholipids have good biocompatibility and significant amphiphilic characteristics, making them the main and suitable dosage form or excipient in drug formulations, thereby achieving better therapeutic effects. C2 Ceramide-1-phosphatecan be used in drug delivery research .

HY-144005B

C16 PEG5000 Ceramide C16 PEG Ceramide (MW 5000)	Drug Delivery
C16 PEG5000 Ceramide (C16 PEG Ceramide (MW 5000)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .

HY-144008

C8 PEG-Ceramide	Drug Delivery
C8 PEG-Ceramide is a lipid product. C8 PEG-Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .

HY-144005A

C16 PEG750 Ceramide C16 PEG Ceramide (MW 750)	Drug Delivery
C16 PEG750 Ceramide (C16 PEG Ceramide (MW 750)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies .

HY-144008A

C8 PEG5000 Ceramide	Drug Delivery
C8 PEG5000 Ceramide is a lipid product. C8 PEG5000 Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .

HY-167803

N-(2'-(R)-Hydroxynervonoyl)-D-erythro-sphingosine 24:1(2R-OH) Ceramide	Drug Delivery
N-(2'-(R)-Hydroxynervonoyl) -d-erythro-Sphingosine (24:1(2R-OH) Ceramide) is a biochemical reagent .

HY-157718

1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine

Drug Delivery

1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.

Cat. No.	Product Name	Target	Research Area

HY-P1975

Aureobasidin A 2 Publications Verification Basifungin	Fungal Parasite	Infection Inflammation/Immunology
Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease Cancer
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-P1103

CTCE-9908 1 Publications Verification	CXCR	Cancer
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P10026

Nisotirostide LY-3457263	Neuropeptide Y Receptor	Metabolic Disease
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P1103A

CTCE-9908 TFA	CXCR	Cancer
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .

HY-P4757

N1-Glutathionyl-spermidine disulfide	Parasite	Others
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P4070

Insulin icodec	Peptides	Metabolic Disease
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec can be used for the research of type 2 diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-141578

C18:1-Ceramide	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
C18:1-Ceramide is a ceramide subspecies. C18:1-Ceramide can be used in the study of type 2 diabetes

HY-P1975

Aureobasidin A 2 Publications Verification Basifungin	Infection Structural Classification Microorganisms Antifungal Classification of Application Fields Antibiotics Source classification Disease Research Inflammation/Immunology Disease Research Fields Other Antibiotics	Fungal Parasite
Aureobasidin A (Basifungin) is a cyclic peptide antibiotic with oral activity. Aureobasidin A is an inhibitor of inositol phosphorylated ceramide synthetase AUR1. Aureobasidin A has antifungal and antiparasitic activity .

HY-13626

Spisulosine ES-285	Alkaloids Animals Classification of Application Fields Other Alkaloids Marine natural products Source classification Other marine organisms Disease Research Fields Cancer	PKC Apoptosis
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .

HY-129099A

N-Desmethyltamoxifen hydrochloride	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-112016

C20 Ceramide N-Arachidoyl-D-sphingosine	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
C20 Ceramide is a natural 20:0 ceramide that is abundant in the brain .

HY-100354

C16-Ceramide 2 Publications Verification	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	MDM-2/p53 Apoptosis Endogenous Metabolite
C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding .

HY-129099

N-Desmethyltamoxifen	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation .

HY-129099AR

N-Desmethyltamoxifen hydrochloride (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	PKC Estrogen Receptor/ERR Drug Metabolite Endogenous Metabolite
N-Desmethyltamoxifen (hydrochloride) (Standard) is the analytical standard of N-Desmethyltamoxifen (hydrochloride). This product is intended for research and analytical applications. N-Desmethyltamoxifen hydrochloride is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen hydrochloride is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].

HY-100355R

*C18-Ceramide* (Standard)**	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite Reference Standards
C18-Ceramide (Standard) is the analytical standard of C18-Ceramide. This product is intended for research and analytical applications. C18-Ceramide can promote exocytosis of glutamate from damaged neurons. C18-Ceramide promotes cell death in glioma cells. Ceramides is involved in diverse cellular functions, such as differentiation, cell cycle progression, cell-cell adhesion, senescence, and apoptosis .

HY-117081

*C30(ω-hydroxy) Ceramide* (d18:1/30:0)**	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
C30(ω-hydroxy) Ceramide (d18:1/30:0), a sphingolipid, is an epidermis-specifically vital component of the water barrier in mammalian skin. C30(ω-hydroxy) Ceramide (d18:1/30:0) is expressed in epidermal keratinocytes and male germ cells during their differentiation and maturation. C30(ω-hydroxy) Ceramide (d18:1/30:0) deficiency in the epiderm of Elovl4 deletion or mutation mice .

HY-145520

*(±)-2'-hydroxy Ceramide* (d18:0/18:0)** (±)-2'-hydroxy Cer(d18:0/18:0)	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
(±)-2'-hydroxy Ceramide (d18:0/18:0) is a sphingomyelin that can be isolated from mammalian platelets stimulation by ADP .

HY-N6723

Fumonisin B2	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics	Acyltransferase
Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of *sphingosine N-acyltransferase (ceramide* synthase)** and disrupts de novo sphingolipid biosynthesis .

HY-N10634

D-Glucosyl-β-1,1′-N-palmitoylsphingosine C16 Glucosyl(β) Ceramide (d18:1/16:0)	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Others
D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

HY-N6730

Hydrolyzed Fumonisin B1 Aminopentol	Natural Products Microorganisms Source classification	Apoptosis
Hydrolyzed Fumonisin B1 (Aminopentol) is the backbone and main hydrolysis product of the mycotoxin Fumonisin B1 (HY-N6719). Hydrolyzed Fumonisin B1 can weakly inhibit ceramide synthase .

HY-N6719

Fumonisin B1 5 Publications Verification	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Endogenous metabolite Disease Research Fields Other Antibiotics	Acyltransferase
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of *sphingosine N-acyltransferase (ceramide* synthase)** and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-100355

C18-Ceramide	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
C18-Ceramide is a bioactive molecule with multiple functions in cells, can cross the blood-brain barrier, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology .

Cat. No.	Product Name	Chemical Structure

HY-100354S3

*C16-Ceramide-d9*
C16-Ceramide-d₉ is deuterium labeled C16-Ceramide.

HY-100354S4

*C16-Ceramide-d31*
C16-Ceramide-d₃₁ is deuterium labeled C16-Ceramide.

HY-100355S1

*C18-Ceramide-d7*
C18-Ceramide-d₇ is deuterium labeled C18-Ceramide.

HY-134575S

*C24:1-Ceramide-d7*
C24:1-Ceramide-d₇ is the deuterium labeled C24:1-Ceramide[1].

HY-141578S

*C18:1-Ceramide-13C18*
C18:1-Ceramide- ¹³C₁₈ is a ¹³C-labeled C16-Ceramide[1].

HY-19542S1

*C6 Ceramide-d11*
C6 Ceramide-d₁₁ is deuterated labeled C6 Ceramide (HY-19542). C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .

HY-166315S

*C15-Ceramide-d7*
C15-Ceramide-d₇ is deuterium labeled C15-Ceramide. C15-Ceramide is an ester product .

HY-100355S

*C18-Ceramide-d3*
C18-Ceramide-d₃ is the deuterium labeled C18-Ceramide[1].

HY-134508S

*C24-Ceramide-d7*
C24-Ceramide-d₇ is the deuterium labeled C24-Ceramide[1].

HY-146902S

*C15 Ceramide-1-phosphate-d7*
C15 Ceramide-1-phosphate-d₇ is deuterium labeled C15 Ceramide-1-phosphate.

HY-W698686S

β-Galactosyl-C18-ceramide-d35

β-Galactosyl-C18-ceramide-d₃5 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .

HY-146935S

*C20:1 Ceramide-d7*
C20:1 Ceramide-d₇ is deuterium labeled C20:1 Ceramide.

HY-146760S

*C15 Glucosyl(β) ceramide-d7*
C15 Glucosyl(β) ceramide-d₇ is deuterium labeled C15 Glucosyl(β) ceramide.

HY-146906S

*C18 Glucosyl(ß) ceramide-d5*
C18 Glucosyl(ß) ceramide-d₅ is deuterium labeled C18 Glucosyl(ß) ceramide.

HY-146934S

*C22:1 Ceramide-d7*
C22:1 Ceramide-d₇ is deuterium labeled C22:1 Ceramide.

HY-146936S

*C16:1 Ceramide-d7*
C16:1 Ceramide-d₇ is deuterium labeled C16:1 Ceramide.

HY-141578S1

*C18:1 Ceramide-d7*
C18:1 Ceramide-d₇ is deuterium labeled C18:1 Ceramide.

HY-19542S

Ceramide C6-d7
Ceramide C6-d₇ is the deuterium labeled Ceramide C6. Ceramide C6, a Ceramide pathway activator, is an exogenous short-chain ceramide which can induce apoptosis of multiple cancer cells[1][2][3].

HY-146907S

*C18:1 Glucosyl ceramide-d5*
C18:1 Glucosyl ceramide-d₅ is deuterium labeled C18:1 Glucosyl ceramide.

HY-W654105

*C18-Ceramide-13C2,d2*
C18-Ceramide-13C2,d2 is a deuterated labeled C18-Ceramide-13C2,d2 .

HY-116258S

*C16 Ceramide-d7 (d16:1,C16:0)*
C16 Ceramide-d7 (d16:1,C16:0) is the deuterium labeled C16 Ceramide (d16:1,C16:0)[1].

HY-100354S

*C16-Ceramide-13C16*
C16-Ceramide- ¹³C₁₆ is a ¹³C-labeled Glycine ethyl ester monohydrochloride[1].

HY-W214059S

N-Acetyl-S-methyl-L-cysteine-d3
N-Acetyl-S-methyl-L-cysteine-d₃ is the deuterium labeled C18:1-Ceramide[1].

HY-167593S

C18:0-d7 GM1 Ceramide
C18:0-d₇ GM1 Ceramide is deuterium labeled C18:0 GM1 Ceramide .

HY-167594S

C18:0-d7 GM2 Ceramide
C18:0-d₇ GM2 Ceramide is deuterium labeled C18:0 GM2 Ceramide .

HY-167595S

*C18:0-d7 GD3 Ceramide* (d18:1/18:0-d7)**
C18:0-d₇ GD3 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GD3 Ceramide (d18:1/18:0) .

HY-167596S

*C18:0-d7 GD2 Ceramide* (d18:1/18:0-d7)**
C18:0-d₇ GD2 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GD2 Ceramide (d18:1/18:0) .

HY-167598S

*C18:0-d7 GB4 Ceramide* (d18:1/18:0-d7)**
C18:0-d₇ GB4 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GB4 Ceramide (d18:1/18:0) .

HY-167597S

*C18:0-d7 GD1b Ceramide* (d18:1/18:0-d7)**
C18:0-d₇ GD1b Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 GD1b Ceramide (d18:1/18:0) .

HY-167599S

*C18:0-d7 Fuc-GM1 Ceramide* (d18:1/18:0-d7)**
C18:0-d₇ Fuc-GM1 Ceramide (d₁₈:1/18:0-d₇) is deuterium labeled C18:0 Fuc-GM1 Ceramide (d18:1/18:0) .

HY-N6723S

Fumonisin B2-13C34
Fumonisin B2- ¹³C₃₄ is the ¹³C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of *sphingosine N-acyltransferase (ceramide* synthase)** and disrupts de novo sphingolipid biosynthesis .

HY-N6719S

Fumonisin B1-13C34
Fumonisin B1- ¹³C₃₄ is the ¹³C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of *sphingosine N-acyltransferase (ceramide* synthase)** and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .

HY-13626S

Spisulosine-d3
Spisulosine-d₃ (ES-285-d₃) is deuterium labeled Spisulosine (HY-13626). Spisulosine is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .

HY-141582S

Ceramide 3-d3

Ceramide 3-d₃ (N-Stearoyl phytosphingosine-d₃) is deuterium labeled Ceramide 3. C18 Phytoceramide (t18:0/18:0) (Cer(t18:0/18:0)) is a bioactive sphingolipid found in the stratum corneum of Saccharomyces cerevisiae, wheat grain, and mammalian epidermis. Cer(t18:0/18:0) consists of a phytosphingosine backbone amine linked to a C18 fatty acid chain. Cer(t18:0/18:0) has the function of regulating apoptosis, cell differentiation, proliferation of smooth muscle cells and inhibition of mitochondrial respiratory chain. It also suppresses the expression of allergic cytokines IL-4, TNF-α, and transcription factors c-Jun and NF-κB in histone-stimulated mouse skin tissue. Formulations containing cer(t18:0/18:0) have been used as skin protectants in cosmetics as they reduce water loss and prevent epidermal dehydration and irritation .

HY-N10634S

D-Glucosyl-β-N-palmitoylsphingosine-d3
D-Glucosyl-β-N-palmitoylsphingosine-d₃ (N-ω-Cd₃-Hexadecaoyl-glucopsychosie) is deuterium labeled D-Glucosyl-β-1,1′-N-palmitoylsphingosine. D-Glucosyl-β-1,1′-N-palmitoylsphingosine (C16 Glucosyl(β) Ceramide (d18:1/16:0)) is an endogenous Mincle ligand possessing immunostimulatory activity .

HY-117057S

Hexaenoic acid-d6

Hexaenoic acid-d₆ is deuterium labeled Hexaenoic acid. Very long chain polyunsaturated fatty acids (VLCPUFAs) are important components of ceramides and sphingomyelin and are present in retina, sperm, and brain. Tetratriaconta-16(Z),19(Z),22(Z),25(Z),28(Z),31(Z)-hexaenoic acid is a C34:6 VLCPUFA whose specific biological actions are largely unknown. This VLCPUFA, along with others, has been investigated for its role in activating protein kinase C .

Cat. No.	Product Name		Classification

HY-144005

C16 PEG2000 Ceramide C16 PEG Ceramide (MW 2000)		Pegylated Lipids
C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide. C16 PEG2000 Ceramide can be used for lipid carrier to delivery. C16 PEG2000 Ceramide induces autophagy. C16 PEG2000 Ceramide can be used for cancer research .

HY-134508

C24-Ceramide		Phospholipids
C24-Ceramide is a sphingolipid that can be used for the lipid membranes composed. C24-Ceramide induces time-dependent changes in membrane properties. C24-Ceramide induces membrane reorganization .

HY-144008

C8 PEG-Ceramide		Pegylated Lipids
C8 PEG-Ceramide is a lipid product. C8 PEG-Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .

HY-144008A

C8 PEG5000 Ceramide		Pegylated Lipids
C8 PEG5000 Ceramide is a lipid product. C8 PEG5000 Ceramide can synthesize lipid bilayer carrier and can be used for drug delivery .

HY-157718

1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine		Phospholipids
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Ceramides

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products